Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate

Author(s)

Silva dos Santos, Priscilla de Nazare ; de Souza, Aglecio Luiz ; Batista, Gisele Almeida ; Melhado-Kimura, Vaneska ; de Lima, Gabriel Araujo ; Bahamondes, Luis ; Fernandes, Arlete

• Document type: Journal article
• Source: ARCHIVES OF GYNECOLOGY AND OBSTETRICS; v. 294, n. 6, p. 1331-1336, NOV 2016.
• Web of Science Citations: 1

Abstract

Weight gain has been cited by women as one of the main reasons for discontinuation of the contraceptive depot medroxyprogesterone acetate (DMPA). This study aimed to evaluate binge eating and the biochemical markers of appetite in new DMPA users. In this prospective non randomized study with adult healthy women, twenty-eight users of DMPA and twenty-five users of a copper intrauterine device (IUD) were paired for age (+/- 1 year) and body mass index (BMI) (+/- 1 kg/m(2)). We evaluated binge eating using the Binge Eating Scale (BES), the serum levels of neuropeptide Y, leptin and adiponectin, and the BMI at baseline and after 12 months in both groups. For statistical analysis was used ANOVA for to compare the means of the repeated measurements. Mean age was 29.6 and 28.6 years and BMI was 23.9 and 24.5 kg/m(2) for the DMPA and IUD groups, respectively. After 12 months, the frequency of the scores of binge eating remained low in both groups. There were no significant differences between the groups at 12 months with respect to BMI, levels of NPY, leptin, adiponectin, and BES scores. Healthy adult women did not present with central stimulation of appetite or binge eating disorder in their first year after starting use of DMPA. This study reinforces the use of the contraceptive DPMA and the need for guidance related to living a healthy lifestyle for women who attribute the increase of body weight to the use of the method. (AU)

• FAPESP's process: 11/14827-9 - Evaluation of food behavior disorders, bone mineral density (BMD) and coagulation parameters in new quarterly users of contraceptive depot medroxyprogesterone acetate (DMPA) and controls in one year of follow up
• Grantee: Luis Guillermo Bahamondes
• Support Opportunities: Regular Research Grants
• FAPESP's process: 09/53293-0 - Prospective study for evaluation of the insulin resistance, lipid metabolism and sub clinical cardiovascular disease in women who initiate the depot-medroxyprogesterone acetate (DMP A) contraceptive method with in follow-up for two years. (Project of scientific research)
• Grantee: Luis Guillermo Bahamondes
• Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)